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MiceThe present study evaluated the antinociceptive effect of the pro-inﬂammatory cytokines inhibitor diacerein
in mice and its possible mechanism of action. The antinociception produced by diacerein was tested at differ-
ent sites of action, moreover selective antagonists or agonists were used to identify the mechanism that may
be involved in its antinociceptive action against acetic acid-induced visceral pain. Diacerein administered sys-
temically (intraperitoneal [i.p.] or intra-gastric [i.g.] routes), supra-spinally (i.c.v.), spinally (i.t.) or peripher-
ally (in association with the irritant agent) inhibited the visceral nociception induced by acetic acid in mice.
Interestingly, diacerein treatment (25 mg/kg, i.p. or 50 mg/kg, i.g.) produced long-lasting (for up to 4 h) in-
hibition of acetic acid-induced nociception. Intraperitoneal treatment of mice with diacerein (25.0 mg/kg)
inhibited somatic nociception induced by i.t. injection of glutamate, NMDA, kainate, and trans-ACPD but
not that caused by AMPA. Diacerein (5.0–25.0 mg/kg) also produced dose related inhibition of interleukin-1β
(IL-1β) and tumor necrosis factor alpha (TNF-α) induced nociception. These results indicate that diacerein pro-
duces antinociception by inhibiting glutamatergic transmission through both ionotropic and metabotropic recep-
tors as well as activity of pro-inﬂammatory cytokines.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Diacerein (4,5-diacetoxy-9,10-dihydro-9,10-dioxo-2 anthracene-
carboxylicacid) is a puriﬁed anthraquinone that is entirely transformed
during absorption into rhein, the active metabolite found in plasma
and synovial ﬂuid. It belongs to a new class of anti-osteoarthritis
drugs, known as “disease modifying osteoarthritis drugs (DMOAD)”
or “chondroprotective agents” (Verbruggen, 2006; Pelletier and
Martel-Pelletier, 2007). For its actions both in vivo and in vitro, diacerein
has been used in the treatment of osteoarthritis and demonstrated ben-
eﬁts in alleviating joint pain in humans and in rodentmodels of the dis-
ease (Pavelka et al., 2007; Pelletier et al., 2000; Tamura et al., 1999,
2001, 2002) (for review see, Hunter and Wise, 2007). Recent data
from our group showed that diacerein inhibits neuropathic pain in-
duced by partial ligation of the sciatic nerve and also producedias Fisiológicas, Universidade
C, Brazil. Tel.: +55 48 3721
).
harmacology, Hotchkiss Brain
, Calgary, Canada T2N 4N1.
vier OA license.anti-allodynic effects against carrageenan- and complete Freund's adju-
vant (CFA)-induced inﬂammatory nociception (Quintão et al., 2005).
Although the mechanisms involved on those actions are still incom-
pletely understood, several studies have shown that diacerein and rhein
decrease pro-inﬂammatory cytokines (such as interleukin-1β [IL-1β]
and tumor necrosis factor alpha [TNF-α]) release and production either
in vitro (Martel-Pelletier et al., 1998; Yaron et al., 1999) or in vivo
(Martel-Pelletier et al., 1998; Moldovan et al., 2000), as well as inhibit
in vitro NF-κβ activation (Mendes et al., 2002). In fact, NF-κβ, a tran-
scription factor that acts as a central mediator of the immune response,
is one of the most important regulators of gene expression among the
family of pro-inﬂammatory mediators (Bonizzi and Karin, 2004;
Yoshida et al., 1999). Moreover, diacerein has been found to prevent
cartilage breakdown (Moore et al., 1998) and protects against Baker's
yeast-induced fever and peritoneal leukocyte migration (Pasin et al.,
2010) due to inhibition of the release of pro-inﬂammatory cytokines.
Although the analgesic effect of diacerein and its action to inhibit
the production and release of pro-inﬂammatory cytokines is well
established, there is a lack of a broader perspective of the extent to
what mechanisms of action may be applied in well-established
models of acute antinociception. Therefore, we designed the present
study to analyze the antinociceptive effects of diacerein against acetic
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pro-inﬂammatory cytokines‐induced somatic pain. Here, we shown
that diacerein exhibited antinociceptive effect in different sites of ac-
tion and that this effect may be related to an inhibition of the
glutamate-pro-inﬂammatory cytokines signaling pathway.
2. Materials and methods
2.1. Animals
Experiments were conducted using male Swiss mice (25–35 g),
housed at 22±2 °C under a 12-h light/12-h dark cycle (lights on at
06:00) and with access to food and water ad libitum. Mice were accli-
matized to the laboratory for at least 1 h before testing and were used
only once throughout the experiments. The experiments were per-
formed after approval of the protocol (PP00651) by the Institutional
Ethics Committee and were carried out in accordance both with cur-
rent guidelines for the care of laboratory animals and the ethical
guidelines for investigations of experimental pain in conscious ani-
mals (Zimmermann, 1983). The numbers of animals and intensities
of noxious stimuli used were the minimum necessary to demonstrate
consistent effects observed from diacerein treatment.
2.2. Intrathecal injections
Intrathecal injections were given to fully conscious mice using the
method previously described by Hylden and Wilcox (1980). Brieﬂy,
the animals were manually restrained, and a 30-gauge needle con-
nected by a polyethylene tube to a 25 μl Hamilton syringe (Hamilton,
Birmingham, UK) was inserted through the skin and between the ver-
tebrae into the subdural space of the L5–L6 spinal segments. Intrathe-
cal injections were given over a period of 5 s.
2.3. Intracerebroventricular injections
Intracerebroventricular (i.c.v.) administration was performed under
ether anesthesia as previously described (Budni et al., 2007). Brieﬂy, a
0.4 mm external diameter hypodermic needle attached to a cannula,
which was linked to a 25 μl Hamilton syringe was inserted perpendicu-
larly through the skull and no more than 2 mm into the brain of the
mouse. A volume of 5 μl was then administered in the left lateral ventri-
cle. The injection was given over 30 s and the needle remained in place
for another 30 s in order to avoid the reﬂux of the substances injected.
The injection site was 1 mm to left from the mid-point on a line drawn
through to the anterior base of the ears.
2.4. Abdominal constriction response caused by intraperitoneal injection
of acetic acid
The abdominal constrictions resulting from intraperitoneal (i.p.)
injection of acetic acid (0.6%, 450 μl) consist of a contraction of the
abdominal muscle together with a stretching of the hind limbs and
were induced according to procedures described previously (Santos
et al., 2005). The mice were individually placed into glass cylinders
of 20 cm in diameter and the abdominal constrictions were counted
cumulatively over a period of 20 min. Antinociceptive activity was
expressed as the reduction in the number of abdominal constrictions,
i.e. the difference between control animals (mice pre-treated with ve-
hicle) and animals pre-treated with drugs. Micewere pre-treatedwith
diacerein (5–200 mg/kg) or with vehicle (10 ml/kg) by i.p. or
intra-gastric (i.g.) routes, 30 and 60 min before the irritant injection, re-
spectively. In an attempt to evaluate the possible spinal or supra-spinal
antinociceptive action of diacerein, animals were treated with diacerein
(5–100 μg/site) or with vehicle (5 μl/site) by intrathecal (i.t.) or intra-
cerebroventricular (i.c.v.) routes, 10 min prior to injection of acetic acid.In another set of experiments, we also evaluated the effect of
diacerein (100–1000 μg/cavity) co-injected with the irritant agent. In
addition, we investigated the time course of the antinociceptive effect
of diacerein given i.p. (25 mg/kg) or i.g. (50 mg/kg) 0.5, 1, 2, 4 and
6 h before acetic acid administration. Control mice received an equal
volume of vehicle and were observed at the same time intervals.
2.5. Nociception induced by glutamatergic agonists and pro-
inﬂammatory cytokines
Animals received an i.p. injection of diacerein (25 mg/kg) or vehicle
(10 ml/kg) 30 min before i.t. injection of 5 μl of algogen. Injections
were given to fully conscious mice using the method described by
Hylden and Wilcox (1980) (see Section 2.2) with minor modiﬁcations.
The nociceptive response was elicited by glutamate (175 nmol/site),
AMPA (a selective agonist of AMPA-subtype of glutamatergic ionotropic
receptors, 135 pmol/site), NMDA (450 pmol/site, a selective agonist of
the N-methyl-D-aspartic acid [NMDA] glutamatergic ionotropic recep-
tor), kainate (a selective agonist of kainate-subtype of glutamatergic
ionotropic receptors, 110 pmol/site) or trans-ACPD (50 nmol/site, a se-
lective agonist for metabotropic glutamate receptors, that is active at
both group I (mGlu1, mGlu5) and group II (mGlu2, mGlu3) receptors)
(Scheidt et al., 2002; Gadotti et al., 2006; Martins et al., 2011); IL-1β
(1 pg/site) and TNF-α (0.1 pg/site) (Choi et al., 2003; Lapa et al., 2009).
Moreover, to verify the link played by the NMDA receptor on be-
havioral nociception induced by pro-inﬂammatory cytokines, we
assessed the effect of MK-801 (0.05 mg/kg) given i.p., 0.5 h before
test, on TNF-α (1 pmol/site)- and IL-1β (1 pmol/site)-induced
nociception to the mice. Test duration was 15 min for trans-ACPD and
each of the cytokines, 1 min for AMPA, 5 min for NMDA, 4 min for
kainate and 3 min for glutamate. Nociceptive behaviors after i.t. delivery
were deﬁned as a single head movement directed at the ﬂanks or hind
limbs, resulting in contact of the animal's snout with the target organ.
The amount of time (seconds) animals spent licking/biting their hind
paws, tail or abdomen was determined with a chronometer and consid-
ered as nociceptive response (Scheidt et al., 2002; Gadotti et al., 2006;
Martins et al., 2011).
2.6. Reagents
The following substances were used: diacerein (Trb Pharma,
São Paulo, Brazil), acetic acid, Tween 80 and morphine hydro-
chloride (Merck, A.G., Darmstadt, Germany), L-glutamic acid hydro-
chloride (Sigma Chemical Co, St. Louis, USA). Kainic acid (kainate),
(±)-1-Aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD),
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA),
N-methyl-D-aspartic acid (NMDA) and MK-801 (Tocris, Cookson Inc.,
Ellisville, USA), tumor necrosis factor alpha (TNF-α), Interleukin-1β
(IL-1β) (R&D Systems, Minneapolis, USA). All the drugs were dissolved
in isotonic saline solution (0.9% NaCl, pH=5.5) with the exception of
diacerein, which was dissolved in saline plus Tween 80. The
corresponding pH values for the diacerein solution were 5.4, 5.5, and 5.0
for the 20 mg/ml (200 mg/kg), 10 mg/ml (100 mg/kg), and 2.2 mg/ml
(1000 μg/site) solutions, respectively. The ﬁnal concentration of Tween
80 did not exceed 5% and did not cause any effect per se. Also, control
groups for each route of delivery received isotonic saline with 5% of
Tween 80. The choice of the doses of each drug was based on previous
data from our laboratory (Quintão et al., 2005; Gadotti et al., 2006;
Martins et al., 2011).
2.7. Statistical analysis
The results are presented as mean±S.E.M., except the ID50 values
(i.e., the dose of diacerein that reduce the nociceptive response by
50% relative to the control value), which are reported as geometric
means accompanied by their respective 95% conﬁdence limits. The
Fig. 2. Effect of diacerein administered by i.c.v., i.t. or locally (co-injected with acetic
acid) routes on acetic acid-induced nociception. Each column represents the mean of
6–8 animals and the error bars indicate the S.E.M. Control values (C) are from animals
injected with 5% of Tween 80 and the asterisks denote the signiﬁcance relative to the
control group. *Pb0.05, **Pb0.01.
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experiments using GraphPad software (GraphPad software, San
Diego, CA, USA). The statistical signiﬁcance of differences between
groups was detected by t-tests or two-way ANOVA followed by
Tukey's test when appropriate. P-values less than 0.05 were consid-
ered signiﬁcant.
3. Results
3.1. Effect of diacerein on acetic acid-induced abdominal constrictions
In order to verify if diacerein reduces nociceptive signaling under vis-
ceral pain conditions, we examined the response of mice treated with
diacerein after acid acetic injection. The results depicted in Fig. 1A and B
show that diacerein, given by i.p. (30 min earlier) or i.g. (60 min before)
routes, produced dose-related inhibition of acetic acid-induced abdomi-
nal constrictions in mice, with mean ID50 values (with their 95% conﬁ-
dence limits) of 20.6 (16.1–26.2) and 35.6 (30.4–41.7) mg/kg and
inhibition of 86±5% and 76±3%, respectively. Hence, diacerein was 1.8
fold more potent to reduced nociception when delivered by i.p. route
thanwhendelivered through i.g. route. A time-course analysis of the anti-
nociceptive effect of diacerein is show in Fig. 1C and D. Diacerein pro-
duced marked antinociception as early as 30 and 60 min after i.p.
(25 mg/kg) or i.g. (50 mg/kg) administration, respectively. This action
remained signiﬁcant up to 4 h after both systemic treatments. Thus, the
time point (30 or 60 min for i.p. or i.g. routes, respectively) of maximum
effect of diacerein was chosen for all further studies with independent
groups of animals.
Diacerein also inhibited signiﬁcantly the visceral nociceptive re-
sponse when administered i.c.v., i.t. or peripherally (co-injected).
The calculated mean ID50 values were 32.4 (26.6–39.5), 27.1 (18.8–
39.1) and 252.2 (235.2–270.4) μg/site and the inhibitions were 72±
9, 67±9 and 57±4%, respectively (Fig. 2).
3.2. Effect of diacerein on glutamatergic agonists- and pro-inﬂammatory
cytokines-induced nociception
To directly investigate the role of spinal glutamate receptors
and pro-inﬂammatory cytokines in the antinociceptive action of
diacerein, we compared the nociceptive behavior of mice treated with
diacerein after a single intrathecal injection of glutamatergic agonist orFig. 1. Effect of diacerein administered by i.p. (A and C) or i.g. (B and D) routes on acetic a
administered by i.p. route (25 mg/kg, panel C) or orally (50 mg/kg, panel D) on acetic acid
mean of 6–8 animals and the error bars indicate the S.E.M. Control values (C) are from an
to the control group. *Pb0.05, **Pb0.01.pro-inﬂammatory cytokines. As shown in Fig. 3, glutamate (175 nmol/
site, i.t.), AMPA (135 pmol/site, i.t.), NMDA (450 pmol/site, i.t.),
trans-ACPD (50 nmol/site, i.t.), kainate (110 pmol/site, i.t.), TNF-α
(0.1 pmol/site, i.t.) and IL-1β (1 pmol/site, i.t.) administration signiﬁcant-
ly induced nociception in mice (Fig. 3). Diacerein (25 mg/kg, i.p.)
inhibited the nociceptive behavior (licking/biting) responses induced by
glutamate, NMDA, kainate and trans-ACPD with respectively inhibitions
of 53±8, 61±13, 43±15 and 43±10%. In contrast, at the same dose,
diacerein had no effect against AMPA-induced nociception (Fig. 3). This
possibly indicates that diacerein could act negatively modulating the ac-
tivity of both ionotropic and metabotropic receptors. Furthermore, ad-
ministration of diacerein (5–25 mg/kg, i.p.) produced signiﬁcantly and
dose-dependent attenuation of nociceptive responses induced by TNF-α
and IL-1β. The mean ID50 values from these results were 4.7 (3.2–7.0)
and 10.8 (9.8–11.7) mg/kg and the observed inhibitions were 100 and
93±5%, respectively (Fig. 4).3.3. Effect of MK-801 on pro-inﬂammatory cytokine-induced nociception
Fig. 5 shows that MK-801, given i.p. (0.05 mg/kg, 30 min before),
signiﬁcantly inhibited the nociceptive response induced by the i.t.cid-induced nociception. Insert: Time-course of the antinociceptive effect of diacerein
-induced nociception. Each column (bar graphs) or point (line graphs) represents the
imals injected with 5% of Tween 80 and the asterisks denote the signiﬁcance relative
Fig. 3. Effect of diacerein administered by i.p. route on glutamate-, AMPA-, NMDA-, kainate- and trans-ACPD‐induced nociception. Each group represents themean of 6–8 animals and the error
bars indicate the S.E.M. Control values (black bars) are from animals injected with 5% of Tween 80 and the asterisks denote the signiﬁcance relative to the control group. *Pb0.05; **Pb0.01.
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respectively.
4. Discussion
This work demonstrates that diacerein elicits signiﬁcant, dose-
dependent and long-lasting antinociception in acute nociception in
mice. Several studies demonstrate that diacerein is an effective and
well-tolerated agent for the treatment of osteoarthritis (Tamura
et al., 1999, 2001) and that rhein, an active metabolite of diacerein, in-
hibits certain pro-inﬂammatory cytokines such as interleukin-1β
(IL-1β) and tumor necrosis factor alpha (TNF-α), besides controls
the production of many pro-inﬂammatory mediators associated to
painful pathophysiological conditions, such as rheumatoid arthritis
and osteoarthritis (Martel-Pelletier, 1998; Pelletier et al., 2000;
Pietrangelo et al., 1998; Tamura et al., 1999, 2001; Yaron et al.,
1999). Our group has shown that diacerein is able to inhibit in mice
neuropathic pain induced by partial sciatic nerve ligation and inﬂam-
matory chronic pain induced by Complete Freund's Adjuvant (CFA) at
a dose that do not seem to be directly associated with nonspeciﬁc sed-
ative or muscle-relaxant actions because it did not affect the perfor-
mance of mice on the rota-rod apparatus or their locomotor activity
in the open-ﬁeld test (Quintão et al., 2005).
Our results show that diacerein administered systemically (i.p. or i.g.
routes), supra-spinally (i.c.v.), spinally (i.t.) or peripherally (co-injected
in association with the irritant agent) produced signiﬁcant inhibition of
nociception caused by intraperitoneal injection of acetic acid, demon-
strating that diacerein produces antinociception in different sites ofFig. 4. Effect of diacerein administered by i.p. route on TNF-α (panel A) and IL-1β (panel B) indu
the S.E.M. Control values (black bars) are from animals injected with 5% of Tween 80 and the asaction (peripheral, spinal and supra-spinal). Acetic acid-induced writh-
ing in mice is described as a typical model for visceral inﬂammatory
nociception that has long been used as a screening tool for the assess-
ment of analgesic or anti-inﬂammatory properties of new agents
(Tjosen and Hole, 1997). At the cellular level, protons depolarize senso-
ry neurons by directly activating a non-selective cationic channel local-
ized on cutaneous, visceral and other types of nocisponsive peripheral
afferent C-ﬁbers (Reeh and Kress, 2001; Julius and Basbaum, 2001). It
has been suggested that acetic acid acts by releasing endogenous in-
ﬂammatory mediators of the nociceptive neurons (Collier et al., 1968),
such as bradykinin, prostaglandins and pro-inﬂammatory cytokines,
when injected intraperitoneally (Ribeiro et al., 2000). The main cyto-
kines involved in nociception induced by acetic acid are TNF-α, IL-1β
and interleukin 8, and they are released from resident peritoneal mac-
rophages and mast cells (Ribeiro et al., 2000). The concentration of glu-
tamate and aspartate in the cerebrospinal ﬂuid was increased after the
injection of acetic acid (Fields et al., 1991; Zhu et al., 2004). Further-
more, this test is sensitive to non-steroidal anti-inﬂammatory drugs
(NSAIDs), narcotics and other centrally acting drugs (Collier et al.,
1968).
We also observed that diacerein effectively inhibited nociceptive
responses induced by intrathecal injection of glutamate, thus raising
the possibility that diacerein elicits antinociceptive activity by
inhibiting glutamatergic transmission in the spinal cord. Moreover,
selective agonists of each type of ionotropic and metabotropic gluta-
matergic receptors were used to investigate whether this action was
receptor-speciﬁc. The results showed that diacerein inhibited the no-
ciceptive response induced by NMDA, kainate and trans-ACPD, butced-nociception. Each group represents themean of 6–8 animals and the error bars indicate
terisks denote the signiﬁcance relative to the control group. *Pb0.05; **Pb0.01.
Fig. 5. Effect of the NMDA receptor blocker MK-801 administered by i.p. route on
TNF-α and IL-1β induced-nociception. Each group represents the mean of 6–8 animals
and the error bars indicate the S.E.M. Control values (black bars) are from animals
injected with 5% of Tween 80 and the asterisks denote the signiﬁcance relative to the
control group. ***Pb0.01.
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tant neurotransmitter controlling the excitation of neurons within
the dorsal horn of the spinal cord as a result of impulses arriving
from primary afferent ﬁbers. Furthermore, it has been demonstrated
that activation of the NMDA receptor promotes induction of immedi-
ate early genes and further production of nociceptive and/or inﬂam-
matory mediators, such as prostaglandins (PG) and nitric oxide
(NO) and pro-inﬂammatory cytokines (Hill, 2001). Thus, part of the
antinociceptive effect mediated by diacerein might be due to a direct
effect on pro-inﬂammatory cytokines released after glutamate ago-
nist injection. Of note, our group recently demonstrated that the
NMDA blocker MK-801 also inhibited nociception induced by i.t. in-
jection of glutamate, NMDA and trans-ACPD (Gadotti et al., 2006).
Our results have shown that treatment of mice with diacerein was
able to inhibit the nociceptive behavior induced by i.t. injection of the
pro-inﬂammatory cytokines IL-1β and TNF-α. Pro-inﬂammatory cyto-
kines released by peripheral injury mediate hyperalgesia and are in-
volved in the sensitization of nociceptive ﬁbers peripherally and
centrally (Skott, 2003). Their primary contribution to hypersensitivity
results from potentiation of the inﬂammatory response and increased
production of proalgesic agents such as prostaglandins, nerve growth
factor (NGF) and bradykinin (Basbaum et al., 2009). It is well known
that TNF-α and IL-1β released from astrocytes enhance neuronal excit-
ability and synaptic strength through the enhancement of the NMDA
and AMPA subtype of glutamatergic receptors and also enhance the
number of those receptors in the neuronal membrane (Stellwagen
and Malenka, 2006). Moreover, IL-1β enhances Ca2+ inﬂux through
the NMDA receptor in the spinal cord contributing to nociceptive trans-
mission (Viviani et al., 2003). Recently, Zhang et al. (2008) showed that
IL-1β phosphorylates theNR-1 subunit of the NMDA receptor leading to
its activation. On the other hand, glutamate is able to activate glial cells
leading to the subsequent release of pro-inﬂammatory cytokines, such
as TNF-α and IL-1β (see review by Wieseler-Frank et al., 2004). Here,
we also show that MK-801 is able to reduce nociceptive response in-
duced by i.t. injection of TNF-α and IL-1β. This result may be linked to
the fact that pro-inﬂammatory cytokines, such as TNF-α and IL-1β, in-
duce glutamate and SP release from nerve terminals in the spinal
cord, which then contribute to nociceptive transmission (Basbaum et
al., 2009). Our results show that diacerein produces antinociception
against acetic acid-induced visceral as well as glutamatergic agonists
and pro-inﬂammatory cytokines-induced somatic pain. Thus, diacerein
could affect pain either by preventing the release of glutamate from pri-
mary afferents induced by pro-inﬂammatory cytokines and/or by
inhibiting the activation of projection neurons by glutamate, through
the inhibition of NMDA, kainate and metabotropic receptors, which
contribute to the production and/or release of those pro-inﬂammatorycytokines such TNF-α and IL-1β in the spinal cord. However, additional
studies will be required to conﬁrm these hypotheses.
4.1. Conclusions
The ﬁndings of the presentwork provide evidence that diacerein ex-
erts a rapid onset, relatively long-lasting and pronounced systemic, spi-
nal, supra-spinal and locally antinociceptive action against acetic
acid-induced visceral nociception in mice. In addition, a mechanism re-
lated to the inhibition of glutamate receptor activity and the inhibition
of the activity of pro-inﬂammatory mediators seems to contribute to
the analgesic properties of diacerein.
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